ADITXT THERAPEUTICS
Aditx Therapeutics is a biotechnology company developing a novel nucleic acid-based technology to selectively suppress immune cells involved in the rejection of transplanted tissues and organs. The company was founded in 2017 by Amro Albanna and is based in Loma Linda, California, United States.
ADITXT THERAPEUTICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2017-09-01
Address:
Loma Linda, California, United States
Country:
United States
Website Url:
http://www.aditxt.com
Total Employee:
1+
Status:
Active
Contact:
(909) 488-0844
Email Addresses:
[email protected]
Total Funding:
22.4 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Sonnet BioTherapeutics
Sonnet BioTherapeutics is a biotechnology company for innovating biologic drugs of the single or bispecific mechanism of action.
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-12-28 | AiPharma | AiPharma acquired by Aditxt Therapeutics | N/A |
Official Site Inspections
http://www.aditxt.com Semrush global rank: 3.24 M Semrush visits lastest month: 5.13 K
- Host name: az1-ts112.a2hosting.com
- IP address: 106.0.62.83
- Location: Dhaka Bangladesh
- Latitude: 23.7121
- Longitude: 90.4598
- Timezone: Asia/Dhaka
- Postal: 1362
More informations about "Aditxt Therapeutics"
Corporate Team - Aditxt, Inc.
Leadership We have assembled a team of experts coming from a variety of different scientific fields and commercial backgrounds, with a collective experience that range from founding startup biotech companies, to developing …See details»
Investor Relations - Aditxt, Inc.
Investor Presentation May 18, 2021 Shareholder Letter from Amro Albanna View pageSee details»
Aditxt Therapeutics - Crunchbase Investor Profile
Aditxt Therapeutics may be growing as evidenced by its recent strategic acquisitions. The company has signed an agreement to acquire Appili Therapeutics, which is a significant move indicating expansion. Additionally, …See details»
aditXt (Nasdaq: ADTX) - LinkedIn
Aditxt is a social innovation platform. Every year, billions of individuals face health challenges such as autoimmune diseases, misdiagnosis, infectious diseases, organ failure, reproductive ...See details»
Aditxt Signs Second Amendment to the Arrangement Agreement …
MOUNTAIN VIEW, Calif., July 25, 2024--(BUSINESS WIRE)--Aditxt, Inc. ("Aditxt") (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health …See details»
Aditxt, Inc. (ADTX) Stock Price, News, Quote & History
Find the latest Aditxt, Inc. (ADTX) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Aditxt, Inc. (ADTX) Stock Price, News, Quote & History - Yahoo …
Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its …See details»
Aditxt Subsidiary Adimune Signs Clinical Trial …
May 5, 2023 Aditxt®, Inc. announces that its subsidiary Adimune,™ Inc. has signed a clinical trial agreement with Mayo Clinic to study Stiff Person Syndrome. ... According to the National Organization of ...See details»
Mission and Values – Aditxt, Inc.
Aditxt is an innovation platform commercializing promising biotechnologies with focus on monitoring and modulating the immune system. We are developing ADI products for organ …See details»
Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem ...
Dec 12, 2023 Aditxt looks to accelerate Evofem into the global non-hormonal birth control market valued at $27.7 billion in 2022 and is projected to grow to $52.2 billion by 2031See details»
Aditxt Signs Share Exchange Agreement to Acquire AiPharma
Dec 28, 2021 Second, Aditxt would then acquire the remaining 90.5% of the issued and outstanding equity interests in AiPharma in exchange for the issuance of approximately 39.9 …See details»
Aditxt and Evofem Amend and Restate Merger Agreement, …
Jul 17, 2024 Aditxt has a diverse innovation portfolio, including Adimune™, Inc., which is leading the charge in developing a novel class of therapeutics for retraining the immune system to …See details»
Aditxt, Inc.
Aditxt’s solution aims to stop the precise immune system malfunction in its tracks, allowing the production of insulin. Immunotherapy that achieves this would be the first permanent cure for …See details»
Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics …
Apr 2, 2024 MOUNTAIN VIEW, Calif., April 02, 2024--Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising …See details»
Aditxt, Inc. Enters into Definitive Agreement to Acquire ... - Nasdaq
Dec 12, 2023 Aditxt looks to accelerate Evofem into the global non-hormonal birth control market valued at $27.7 billion in 2022 and is projected to grow to $52.2 billion by 2031. …See details»
Home - AditxtScore
While it is impossible to ensure every encounter is infection free, AditxtScore for COVID-19 can help individuals gain a better understanding of their immunity status. Aditxt’s monitoring …See details»
ADITXT, INC. NOMINATING AND CORPORATE COMMITTEE …
Aug 18, 2021 by the Board of Directors (the “Board”) of Aditxt, Inc. (the “Company”), in order to, among other things: 1. develop and recommend to the Board the corporate governance …See details»
Aditxt, Inc. (ADTX) Stock Price, Quote & News - Stock Analysis
Nov 19, 2024 Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and …See details»
Contact - Aditxt, Inc.
How can we help?See details»